Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
about
Cardiac toxicity of trastuzumab in elderly patients with breast cancerAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerCardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the MatterTwenty years of anti-HER2 therapy-associated cardiotoxicityRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerPertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Therapeutic Considerations in Treating HER2-Positive Metastatic Breast CancerCardiovascular toxicities from systemic breast cancer therapy.An update on cardio-oncology.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.The expanding role of pertuzumab in the treatment of HER2-positive breast cancerCardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast CancerA plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and OutcomesBreast cancer, version 3.2013: featured updates to the NCCN guidelines.Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.Pertuzumab for the treatment of breast cancer.Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Cardiotoxicity of anticancer treatments.Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.Pertuzumab for the treatment of breast cancer: a safety review.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.Breast cancer treatment-induced cardiotoxicity.Enhanced Cardiac Testing in a Dual Anti-HER2 Regimen: What Have We Learned?Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.
P2860
Q26741182-8B550C8A-36B7-4C4D-A247-33AD75B18E0DQ27343148-BD897988-4733-4C68-B488-53205CD6F188Q27853134-D737DBC9-D5CE-4225-8932-1C7866DF1F30Q28075864-92A16336-507A-424F-95B3-5F1E42EB0776Q28079391-15A2C5D7-F39B-4E36-B6D8-1E560472E617Q28083123-3173B2B0-92F9-4652-97C7-DEAC56908B90Q28237833-4F29886E-9DE6-489A-A0AB-075BBF806D53Q28291395-EC5F6866-21E8-432E-A657-6BB278FE638EQ30371966-0804F984-D22D-4A68-B818-E3DEED8275E4Q33364587-ABA2827D-7E1F-4653-BAD1-0E29DB4EF60AQ33618685-CC55C83C-8F2B-4AF1-ADE9-FB870C8F2B3CQ33680109-80D40FCF-0E25-4F6C-A71A-7009510F06FFQ33827808-A815E41A-3E63-46DF-AD01-0DB7B475FD70Q34042768-96C31FCD-3B1F-4206-8435-4770E98BA89BQ34268618-86EF7464-1AEC-4332-AFDE-27E871EB82BCQ34630349-86DB62F1-2A45-41B2-9720-EA5E06C1C0E5Q34650059-77FA9397-81AE-4EA5-A198-2002EA7CF5EEQ34664129-070DB3CC-529F-4FC7-8478-73F0696469D4Q35653163-DD606124-538E-4693-8216-77D46DA73DA8Q36788268-0EE2F3E5-7067-477E-B40A-9C828B8BBC53Q37078963-AE4B0F9D-E8B0-439D-B6D1-76FC438E706FQ37301426-086F6CE0-722F-4119-BC59-197EB5C3D82AQ37301435-CA879EE1-E252-4BC7-B589-B7FE8A4AC347Q37675239-350407FC-F241-4F01-B205-D59A993B9480Q37709567-4213776F-BC8D-40A8-9514-84EFDC35F7CDQ38132047-5A83FB28-6465-4163-8720-064A80DEDDE9Q38209463-C47AFB7C-CB13-4370-A3F8-2230B093A7A9Q38209464-4E336EB3-D43E-473B-A88F-9C77A8ECFBD6Q38219674-5DD325B2-FA9B-4B1E-BD8C-0434E98E2843Q38286163-81CE4824-2B2A-4050-9DB7-AF69CB9BF657Q38473331-F970389A-2F3E-473D-9C90-6018723FAE7EQ38573858-A8829B6D-9712-419B-8E8E-227A23CF93EAQ38743961-2F8EA527-40C1-4FA8-909D-A574F89ACBFEQ38776876-8CBF47BB-4CFD-4A6D-BF6E-7E9D298FB487Q38852051-B6B30924-8D6D-4271-B2E5-23AB0731E66BQ38877306-D143DB7C-500B-44EB-9D7A-D4B1F2418A43Q39428826-C42710B2-8635-4B36-A85B-7BA12170691BQ40047999-2C4A2CBA-0908-43AC-8C82-3C2A9E9EBFA3Q40218182-AD6F1110-A9A8-4AC6-805E-EE6AAA905AA2Q41288150-D16D8E26-1EBB-4043-A8C0-12CDA323C910
P2860
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@ast
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@en
type
label
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@ast
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@en
prefLabel
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@ast
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@en
P2093
P2860
P1433
P1476
Cardiac tolerability of pertuz ...... ebo-controlled phase III study
@en
P2093
Adam Knott
David Miles
Dino Amadori
Emma Clark
Graham Ross
José Baselga
Mark C Benyunes
Michael S Ewer
P2860
P304
P356
10.1634/THEONCOLOGIST.2012-0448
P577
2013-03-08T00:00:00Z